论文部分内容阅读
背景:米卡芬净(micafungin)是新一代的棘白菌素类抗真菌药物,它对念珠菌和曲霉感染的治疗十分有效。然而, 这种新药对于某些真菌(包括毛孢子菌)的作用不大。我们观察到4例患者在使用米卡芬净的过程中发生了毛孢子菌感染。我院2001年开始使用该药,但直至2003年1月才发现使用该药过程中会发生毛孢子菌感染。方法:我们查看了Kameda总医院2002年1月到2005年 7月31日所有患者的微生物感染情况记录,发现了4例患者的血培养呈毛孢子菌阳性。
Background: Micafungin is a new generation of echinocandin antifungal agents that is very effective in the treatment of Candida and Aspergillus infections. However, this new drug has little effect on certain fungi, including C. cercospora. We observed that Cephalosporium infections occurred in 4 patients during the use of micafungin. The drug was started in our hospital in 2001, but it was not until January 2003 that a Cephalosporium infection occurred in the course of using the drug. METHODS: We looked at records of microbial infections in all patients at Kameda General Hospital from January 2002 to July 31, 2005 and found that 4 of the patients had positive cultures of C.cereus.